Pure Global

Efficacy of Peri-neural Platelet Rich Plasma Injection in Treatment of Chemotherapy Induced Peripheral Neuropathy. - Trial NCT05348408

Access comprehensive clinical trial information for NCT05348408 through Pure Global AI's free database. This Phase 2 trial is sponsored by South Egypt Cancer Institute and is currently Not yet recruiting. The study focuses on Chemotherapy-induced Peripheral Neuropathy. Target enrollment is 62 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT05348408
Phase 2
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT05348408
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
Efficacy of Peri-neural Platelet Rich Plasma Injection in Treatment of Chemotherapy Induced Peripheral Neuropathy.
Efficacy of Ultra-sound Guided Peri-neural Platelet Rich Plasma Injection in Treatment of Chemotherapy Induced Peripheral Neuropathy: Randomized Controlled Trial.

Study Focus

platelet rich plasma

Interventional

drug

Sponsor & Location

South Egypt Cancer Institute

Timeline & Enrollment

Phase 2

Apr 01, 2022

Apr 01, 2024

62 participants

Primary Outcome

Change in severity of pain after injection

Summary

This study aims to show the efficacy and safety of ultra-sound guided peri-neural platelet
 rich injection in treatment of chemotherapy induced peripheral neuropathy.

ICD-10 Classifications

Drug-induced polyneuropathy
Paraneoplastic neuromyopathy and neuropathy
Polyneuropathy due to other toxic agents
Idiopathic peripheral autonomic neuropathy
Idiopathic progressive neuropathy

Data Source

ClinicalTrials.gov

NCT05348408

Non-Device Trial